Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $95,869 - $133,996
420 Added 18.48%
2,693 $857,000
Q1 2024

May 14, 2024

SELL
$210.76 - $249.51 $783,605 - $927,678
-3,718 Reduced 62.06%
2,273 $522,000
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $324,898 - $388,493
1,512 Added 33.76%
5,991 $1.32 Million
Q3 2023

Nov 14, 2023

SELL
$211.82 - $248.24 $732,261 - $858,165
-3,457 Reduced 43.56%
4,479 $1.01 Million
Q2 2023

Aug 14, 2023

BUY
$205.19 - $232.99 $1.43 Million - $1.63 Million
6,978 Added 728.39%
7,936 $1.75 Million
Q1 2023

May 15, 2023

SELL
$212.99 - $276.17 $657,074 - $851,984
-3,085 Reduced 76.3%
958 $214,000
Q4 2022

Feb 14, 2023

BUY
$205.95 - $280.43 $456,591 - $621,713
2,217 Added 121.41%
4,043 $1.12 Million
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $122,589 - $147,234
603 Added 49.3%
1,826 $382,000
Q2 2022

Aug 15, 2022

BUY
$174.81 - $241.14 $213,792 - $294,914
1,223 New
1,223 $288,000
Q4 2021

Feb 14, 2022

SELL
$184.32 - $216.08 $339,701 - $398,235
-1,843 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$179.86 - $214.88 $118,707 - $141,820
660 Added 55.79%
1,843 $340,000
Q2 2021

Aug 16, 2021

BUY
$170.47 - $211.93 $201,666 - $250,713
1,183 New
1,183 $212,000
Q3 2020

Nov 16, 2020

SELL
$99.9 - $121.13 $353,046 - $428,073
-3,534 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$92.74 - $125.82 $327,743 - $444,647
3,534 New
3,534 $428,000
Q1 2020

May 15, 2020

SELL
$79.39 - $115.35 $336,375 - $488,737
-4,237 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$78.31 - $95.34 $169,384 - $206,220
-2,163 Reduced 33.8%
4,237 $373,000
Q3 2019

Nov 14, 2019

BUY
$74.85 - $85.99 $43,413 - $49,874
580 Added 9.97%
6,400 $510,000
Q2 2019

Aug 14, 2019

BUY
$76.06 - $120.81 $442,669 - $703,114
5,820 New
5,820 $454,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.4B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.